Guidelines

ACR makes changes to adult, pediatric vaccinations guidance


 

Patients with rheumatic and musculoskeletal diseases may need additional vaccines or different versions of vaccines they were not previously recommended to receive, according to updated guidelines from the American College of Rheumatology (ACR) on vaccinations for these patients. The new guidelines pertain to routine vaccinations for adults and children and are based on the most current evidence. They include recommendations on whether to hold certain medications before or after vaccination. They do not include recommendations regarding COVID-19 vaccines.

For guidance on COVID-19 vaccine timing and frequency, the ACR directs physicians to the CDC’s recommendations for people with mild or severe immunosuppression and the ACR’s previous clinical guidance summary on the topic, last revised in February 2022. The recommendations in the new guidance differ from ACR’s guidance on COVID-19 vaccines on whether and when to hold immunosuppressive medications when patients receive nonlive vaccines. The new guidelines now align more closely with those of EULAR, the Infectious Diseases Society of America, and the CDC’s recommendations for human papillomavirus (HPV), pneumococcal, and shingles vaccines.

A close-up of medical syringe with a vaccine. MarianVejcik/Getty Images

Vaccinations in this population are particularly important because “a leading cause of morbidity and mortality in those with rheumatic diseases is infections, due to the detrimental impact immunosuppression has on the ability for the patient to properly clear the pathogen,” Alfred Kim, MD, PhD, professor of rheumatology at Washington University, St. Louis, told this news organization. While immunosuppressive medications are the most common reason patients with these conditions may have impaired immune function, “some of our patients with autoimmune disease also have a preexisting immunodeficiency that can inherently blunt immune responses to either infection or vaccination,” Dr. Kim explained.

“The authors of the guidelines have done a really nice job of making distinct recommendations based on the mechanism of action of various immunosuppressive medications,” Dr. Kim said. “This helps simplify the process of deciding the timing of vaccination for the health provider, especially for those on multiple immunosuppressives who represent an important proportion of our patients with rheumatic diseases.”

The main change to the guidelines for children, aside from those related to flu vaccination, is in regard to rotavirus vaccination for infants exposed to tumor necrosis factor (TNF) inhibitors or rituximab in utero. Infants prenatally exposed to rituximab should not receive the rotavirus vaccine until they are older than 6 months. Those exposed prenatally to TNF inhibitors should receive the rotavirus vaccine on time, according to the CDC schedule for all infants.

Dr. Alfred Kim, director of the Washington University Lupus Clinic

Dr. Alfred Kim

The new rotavirus recommendations follow data showing that immune responses to rotavirus are blunted in those with infliximab exposure, according to Dr. Kim.

“Thus, this poses a serious theoretical risk in newborns with mothers on [a TNF inhibitor] of ineffective clearance of rotavirus infections,” Dr. Kim said in an interview. “While rotavirus infections are quite common with typically self-limiting disease, sometimes requiring hydration to counteract diarrhea-induced dehydration, this can become severe in these newborns that have [a TNF inhibitor] in their system.”

For adults, the ACR issued the following expanded indications for four vaccines for patients currently taking immunosuppressive medication:

  • Patients aged 18 and older should receive the recombinant zoster vaccine against shingles.
  • For patients aged 27-44 who weren’t previously vaccinated against HPV, the HPV vaccine is “conditionally recommended.”
  • Patients younger than 65 should receive the pneumococcal vaccine.
  • Patients aged 19-64 are conditionally recommended to receive the high-dose or adjuvanted flu vaccine rather than the regular-dose flu vaccine.

Pages

Recommended Reading

Higher prevalence of CPPD and chondrocalcinosis in seronegative than seropositive RA
MDedge Rheumatology
Real-world efficacy and safety of second-line therapies for RA
MDedge Rheumatology
RA: Ozoralizumab shows promise in patients with inadequate response to methotrexate
MDedge Rheumatology
RA: Rapid improvements in patient-reported outcomes with upadacitinib vs abatacept
MDedge Rheumatology
Sarcopenia and poor balance increase risk for vertebral spinal osteoporotic fracture in women with RA
MDedge Rheumatology
Prior bariatric surgery associated with better in-hospital outcomes in patients with RA
MDedge Rheumatology
Safety and efficacy of abatacept in RA-associated ILD
MDedge Rheumatology
Discontinuing bDMARD or tofacitinib appears viable in RA patients achieving stable disease control
MDedge Rheumatology
Real-world data on efficacy of abatacept vs TNFi in ACPA-positive RA
MDedge Rheumatology
Commentary: Concomitant Lung Disease, Drug Efficacy, and Potential Misdiagnosis in RA, August 2022
MDedge Rheumatology